Eli Lilly seeks to extend its winning streak in the general market to 6 years
Eli Lilly has outperformed the S&P 500 for five straight years as Wall Street realized its huge opportunity in obesity…
Eli Lilly has outperformed the S&P 500 for five straight years as Wall Street realized its huge opportunity in obesity…
Shortly after the bell rings, we will buy 300 shares of Bristol Myers Squibb at approximately $56.50. Following the deal,…
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
We are buying 300 shares of Bristol-Myers Squibb at approximately $58 each. Following Wednesday's trade, Jim Cramer's Charitable Trust will…
The new trial data has cemented Club's lead position behind Eli Lilly in the highly competitive anti-obesity drug race. Eli…
We are purchasing 25 shares of Danaher at approximately $229 each. Following Monday's trade, Jim Cramer's Charitable Trust will own…
My Top 10 Things to Watch for Friday, Nov. 15 1. President-elect Donald Trump's decision to nominate prominent vaccine skeptic…
Enthusiasm for Eli Lilly, the club's holding company, needs to be tempered, at least for now, as Wall Street grapples…
GE Healthcare reported a mixed quarter before Wednesday's opening bell. While revenue declined slightly, an improvement in earnings along with…
Shares of Abbott Laboratories rose on Friday after the Club holding company scored a surprise victory in a trial into…